By Rupert Hargreaves Indivior, the opioid dependence treatment maker has today said it will start consultations with shareholders on plans to shift its primary listing to the US in yet another blow to the London Stock Exchange. The firm bought in a secondary listing on the Nasdaq in 2023 and said it would look to maintain a secondary listing in the UK. However, the decision to shift its primary listing marks a big change for the company, which was spun out of consumer health and hygiene giant Reckitt Benckiser back in 2014. The pharmaceutics company makes the Sublocade and Suboxone products fo…